Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.6134 -0.0266 (-4.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
News headline image
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 ↗
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? ↗
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.